Literature DB >> 28497502

Improving outcome of fungal diseases - Guiding experts and patients towards excellence.

Oliver A Cornely1,2, Cornelia Lass-Flörl3, Katrien Lagrou4,5, Valentina Arsic-Arsenijevic6, Martin Hoenigl7,8.   

Abstract

Invasive fungal infections are on the rise and during recent years understanding the epidemiology of fungal infections improved. Over 1 billion people are affected and 25 million patients are at imminent risk of severe organ damage or death due to fungal infection. The European Confederation of Medical Mycology (ECMM), founded in 1993, is the roof organisation of 23 National Medical Mycology Societies in Europe. ECMM fights fungal infections at various levels, by creating and distributing scientific knowledge and promoting scientific exchange. In response to the increasing prevalence and management complexity of invasive fungal infections, ECMM recently launched three additional initiatives (https://www.ecmm.info/). (i) ECMM together with other European infectious diseases societies created a comprehensive set of European guidelines for the diagnostic and therapeutic management of invasive fungal infections. (ii) ECMM founded the ECMM Academy awarding fellow status (FECMM) to outstanding researchers who advanced medical mycology. The academy aims at strengthening networking activities between these researchers. (iii) Centres throughout the world can apply for ECMM Excellence Center Status. Following such application on site auditing of up to three levels of mycological work (clinical, microbiological, epidemiological/clinical trials) evaluates the excellence of a centre along predefined criteria. All three initiatives share a common ambition; they aim at improving outcome of fungal diseases through guiding experts and patients towards excellence. Acknowledging fungal infections as a global problem, all three initiatives explicitly reach out beyond European borders.
© 2017 Blackwell Verlag GmbH.

Entities:  

Keywords:  zzm321990Aspergilluszzm321990; zzm321990Candidazzm321990; academy; guideline; policy; standard of care

Mesh:

Year:  2017        PMID: 28497502     DOI: 10.1111/myc.12628

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  23 in total

1.  Point-of-care diagnosis of invasive aspergillosis in non-neutropenic patients: Aspergillus Galactomannan Lateral Flow Assay versus Aspergillus-specific Lateral Flow Device test in bronchoalveolar lavage.

Authors:  Jeffrey D Jenks; Sanjay R Mehta; Randy Taplitz; Saima Aslam; Sharon L Reed; Martin Hoenigl
Journal:  Mycoses       Date:  2019-01-15       Impact factor: 4.377

2.  Rare mould infections caused by Mucorales, Lomentospora prolificans and Fusarium, in San Diego, CA: the role of antifungal combination therapy.

Authors:  Jeffrey D Jenks; Sharon L Reed; Danila Seidel; Philipp Koehler; Oliver A Cornely; Sanjay R Mehta; Martin Hoenigl
Journal:  Int J Antimicrob Agents       Date:  2018-08-09       Impact factor: 5.283

Review 3.  [Aspergillus in airway material : Ignore or treat?]

Authors:  H J F Salzer; C Lange; M Hönigl
Journal:  Internist (Berl)       Date:  2017-11       Impact factor: 0.743

4.  Antifungal activity of magnoflorine against Candida strains.

Authors:  Jaegoo Kim; Thinh Ha Quang Bao; Yu-Kyong Shin; Ki-Young Kim
Journal:  World J Microbiol Biotechnol       Date:  2018-10-31       Impact factor: 3.312

5.  Video-assisted thoracoscopic surgery for invasive pulmonary fungal infection in haematology patients.

Authors:  Han Ma; Jun Wang; Xiao Ma; Shiying Zheng; Haitao Ma; Jinfeng Ge
Journal:  J Thorac Dis       Date:  2019-07       Impact factor: 2.895

6.  (New) Methods for Detection of Aspergillus fumigatus Resistance in Clinical Samples.

Authors:  Jeffrey D Jenks; Birgit Spiess; Dieter Buchheidt; Martin Hoenigl
Journal:  Curr Fungal Infect Rep       Date:  2019-06-20

7.  Diagnosis of invasive aspergillosis in hematological malignancy patients: Performance of cytokines, Asp LFD, and Aspergillus PCR in same day blood and bronchoalveolar lavage samples.

Authors:  Sven Heldt; Juergen Prattes; Susanne Eigl; Birgit Spiess; Holger Flick; Jasmin Rabensteiner; Gemma Johnson; Florian Prüller; Albert Wölfler; Tobias Niedrist; Tobias Boch; Peter Neumeister; Heimo Strohmaier; Robert Krause; Dieter Buchheidt; Martin Hoenigl
Journal:  J Infect       Date:  2018-07-01       Impact factor: 6.072

8.  Triacetylfusarinine C: A urine biomarker for diagnosis of invasive aspergillosis.

Authors:  Martin Hoenigl; Thomas Orasch; Klaus Faserl; Juergen Prattes; Juergen Loeffler; Jan Springer; Fabio Gsaller; Frederike Reischies; Wiebke Duettmann; Reinhard B Raggam; Herbert Lindner; Hubertus Haas
Journal:  J Infect       Date:  2018-09-26       Impact factor: 6.072

Review 9.  Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy.

Authors:  Jeffrey D Jenks; Helmut Jf Salzer; Juergen Prattes; Robert Krause; Dieter Buchheidt; Martin Hoenigl
Journal:  Drug Des Devel Ther       Date:  2018-04-30       Impact factor: 4.162

10.  Recent Advances and Ongoing Challenges in the Diagnosis of Microbial Infections by MALDI-TOF Mass Spectrometry.

Authors:  Walter Florio; Arianna Tavanti; Simona Barnini; Emilia Ghelardi; Antonella Lupetti
Journal:  Front Microbiol       Date:  2018-05-29       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.